News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,498 Results
Type
Article (40092)
Company Profile (288)
Press Release (666118)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (206655)
Career Advice (2020)
Deals (35744)
Drug Delivery (95)
Drug Development (82149)
Employer Resources (174)
FDA (16228)
Job Trends (14994)
News (349203)
Policy (32756)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (6)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (7)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2562)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (50113)
ALS (90)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (124)
Approvals (16237)
Artificial intelligence (250)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11738)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (205)
Bladder cancer (78)
Brain cancer (28)
Breast cancer (281)
Cancer (2255)
Cardiovascular disease (177)
Career advice (1685)
Career pathing (30)
CAR-T (149)
Cell therapy (420)
Cervical cancer (19)
Clinical research (66875)
Collaboration (842)
Compensation (530)
Complete response letters (19)
COVID-19 (2598)
CRISPR (39)
C-suite (242)
Cystic fibrosis (101)
Data (2198)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (268)
Diagnostics (6376)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (87530)
Editorial (36)
Employer branding (22)
Employer resources (148)
Events (114467)
Executive appointments (725)
FDA (17469)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (103)
Generative AI (19)
Gene therapy (299)
GLP-1 (713)
Government (4430)
Grass and pollen (5)
Guidances (54)
Healthcare (18863)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (114)
Indications (30)
Infectious disease (2740)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (97)
Interviews (315)
IPO (16697)
IRA (40)
Job creations (3679)
Job search strategy (1431)
Kidney cancer (10)
Labor market (38)
Layoffs (469)
Leadership (16)
Legal (7936)
Liver cancer (75)
Lung cancer (320)
Lymphoma (152)
Machine learning (7)
Management (58)
Manufacturing (302)
MASH (67)
Medical device (13382)
Medtech (13387)
Mergers & acquisitions (19595)
Metabolic disorders (681)
Multiple sclerosis (81)
NASH (16)
Neurodegenerative disease (89)
Neuropsychiatric disorders (27)
Neuroscience (1920)
NextGen: Class of 2025 (6538)
Non-profit (4495)
Northern California (2655)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (83)
Pancreatic cancer (83)
Parkinson's disease (149)
Partnered (21)
Patents (233)
Patient recruitment (109)
Peanut (46)
People (57992)
Pharmaceutical (74)
Pharmacy benefit managers (18)
Phase I (20857)
Phase II (29493)
Phase III (21864)
Pipeline (1175)
Policy (137)
Postmarket research (2569)
Preclinical (8868)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (254)
Rare diseases (379)
Real estate (5997)
Recruiting (66)
Regulatory (22452)
Reports (46)
Research institute (2333)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2286)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3621)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (37)
The Weekly (29)
United States (23100)
Vaccines (689)
Venture capitalists (41)
Weight loss (232)
Women's health (35)
Worklife (15)
Date
Today (209)
Last 7 days (905)
Last 30 days (2708)
Last 365 days (33140)
2025 (10511)
2024 (35567)
2023 (40489)
2022 (51639)
2021 (56245)
2020 (54472)
2019 (46904)
2018 (35314)
2017 (32520)
2016 (31953)
2015 (38033)
2014 (31864)
2013 (26784)
2012 (28960)
2011 (29624)
2010 (27684)
Location
Africa (728)
Alabama (58)
Alaska (7)
Arizona (233)
Arkansas (14)
Asia (38779)
Australia (6295)
California (6082)
Canada (2008)
China (533)
Colorado (269)
Connecticut (274)
Delaware (147)
Europe (84224)
Florida (911)
Georgia (203)
Idaho (57)
Illinois (531)
India (25)
Indiana (307)
Iowa (11)
Japan (158)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (893)
Massachusetts (4580)
Michigan (216)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1726)
New Mexico (29)
New York (1736)
North Carolina (1010)
North Dakota (8)
Northern California (2655)
Ohio (202)
Oklahoma (14)
Oregon (35)
Pennsylvania (1369)
Puerto Rico (13)
Rhode Island (33)
South America (1109)
South Carolina (22)
South Dakota (1)
Southern California (2286)
Tennessee (101)
Texas (903)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (557)
West Virginia (3)
Wisconsin (53)
706,498 Results for "ipsen biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
April 16, 2025
·
7 min read
Press Releases
Ipsen announces issuance of €500 million inaugural Rated Public Bond
March 19, 2025
·
8 min read
Press Releases
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
April 29, 2025
·
8 min read
Press Releases
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
March 12, 2025
·
6 min read
Press Releases
Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen
March 4, 2025
·
2 min read
Business
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
PARIS, FRANCE, 06 June 2024 - Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August 19, 2024.
June 6, 2024
·
6 min read
Business
Ipsen appoints Keira Driansky as EVP, President of North America
Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024.
May 2, 2024
·
6 min read
Press Releases
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
October 3, 2024
·
8 min read
Press Releases
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
February 13, 2025
·
8 min read
Drug Development
Gilead, Ipsen Tout Phase III Primary Biliary Cholangitis Data as PDUFA Dates Loom
Gilead Sciences’ primary biliary cholangitis candidate seladelpar and Ipsen’s PBC asset elafibranor both showed encouraging Phase III results Wednesday, as they face looming FDA decision dates.
June 5, 2024
·
2 min read
·
Tyler Patchen
1 of 70,650
Next
